Malignancy after renal transplantation: the role of immunosuppression.
about
Everolimus and Malignancy after Solid Organ Transplantation: A Clinical UpdateReconsidering the detection of tolerance to individualize immunosuppression minimization and to improve long-term kidney graft outcomesImmunosuppressive Medications and Squamous Cell Skin Carcinoma: Nested Case-Control Study Within the Skin Cancer after Organ Transplant (SCOT) CohortTumor site immune markers associated with risk for subsequent basal cell carcinomasNovel diagnostics in renal transplantation.Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score.Hepatocellular carcinoma following renal transplantation.Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute StudyHLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisitionCyclophilin D extramitochondrial signaling controls cell cycle progression and chemokine-directed cell motility.Are patients with inflammatory eye disease treated with systemic immunosuppressive therapy at increased risk of malignancy?Risk of bladder cancer in renal transplant recipients: a meta-analysis.Biomarkers of over-immunosuppression.The need for minimization strategies: current problems of immunosuppression.Kidney transplantation in a patient with end stage renal disease after complete remission of acute promyelocytic leukemia.Mesenchymal stromal cells in renal transplantation: opportunities and challenges.Survival in children requiring chronic renal replacement therapy.Chemotherapy and Transplantation: The Role of Immunosuppression in Malignancy and a Review of Antineoplastic Agents in Solid Organ Transplant Recipients.Tolerogenic dendritic cell therapy in organ transplantation.[Urological follow-up and development of cancer after renal transplantation].Squamous Cell Carcinoma of Skin after 20 Years of Renal Transplantation.Considerations for Pharmacoepidemiological Studies of Drug-Cancer Associations.Minor H antigen matches and mismatches are equally distributed among recipients with or without complications after HLA identical sibling renal transplantation.Prevalence of advanced colorectal neoplasm after kidney transplantation: surveillance based on the results of screening colonoscopy.Histopathology and prognosis of de novo bladder tumors following solid organ transplantation.
P2860
Q28067598-84EC62DC-2971-4980-AF7B-EC873B39CAE3Q28080994-A47D1C32-B35E-4973-AFBD-82DB6581DD23Q33880261-4CECEE41-31E9-4C4F-910A-929A194F03EBQ34042944-08B13DA0-A414-40E9-BAEF-E9284360C2BDQ34503698-7D1BA46B-FB20-49A8-97C2-6E359BA8E8C2Q35153428-E60DF92C-3565-435F-A41E-2CA6E3BFA8EFQ35715435-BBE4B30C-4F9E-4A9C-B8EC-3171FE1CFC76Q35818080-A651D92B-CE48-41DD-8082-D1922C2B150AQ36184954-64F58E9F-713E-4B7F-BD15-45C204CC05B7Q36636078-8FBD4A32-2B49-45A4-B4D6-DF91610D3F74Q36964382-757772E7-94C8-4BDB-9255-444FC0F2720DQ37681727-024AADE4-DAC3-49C6-A1D4-44DD0FF35EB5Q37895908-4F08C0D1-52D8-4B12-ACE7-C3928D05D70EQ38370826-A07A64F5-3D5B-4372-8767-160CE3326FE9Q38460764-6DCFBCC6-CBA8-459D-89B9-788CA05D56B4Q38725481-E4F4AC81-FF07-4A5B-952C-159D7013157FQ38784291-480C98D5-4DD8-44D5-BD25-44097796FADBQ38844500-5DF1F8A4-FC16-4094-9AE7-50BE2D976F89Q39013872-4E81FD44-5F86-4384-86D9-41C48FA21D4BQ40956112-A6314405-9685-4AD3-A912-EC180A213612Q47150342-958D2F9E-9A09-41FF-9E53-77E115FAD7DDQ47270566-7E56AD9C-C13C-4033-9F33-166B42594285Q47842670-A8D4DFAA-D403-43B3-9ED8-D71EC8A292CFQ50594570-79B9DB6F-6F19-4FE0-B89C-50F31964B98AQ53550694-C7E6B8F5-3BE7-4E9C-AE70-00AD52AB9521
P2860
Malignancy after renal transplantation: the role of immunosuppression.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Malignancy after renal transplantation: the role of immunosuppression.
@en
Malignancy after renal transplantation: the role of immunosuppression.
@nl
type
label
Malignancy after renal transplantation: the role of immunosuppression.
@en
Malignancy after renal transplantation: the role of immunosuppression.
@nl
prefLabel
Malignancy after renal transplantation: the role of immunosuppression.
@en
Malignancy after renal transplantation: the role of immunosuppression.
@nl
P2860
P356
P1476
Malignancy after renal transplantation: the role of immunosuppression.
@en
P2093
Josep M Grinyó
P2860
P2888
P304
P356
10.1038/NRNEPH.2010.102
P407
P50
P577
2010-09-01T00:00:00Z
P6179
1024565230